Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus

References

• Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010–20.
   Google Scholar
• Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, et al. Treatment of poor prognosis AML patients using P5C833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol 1999;457:47–56.
   PubMed Web of Science ®Google Scholar
• List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, et al. Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 2002;100:1910–2.
   PubMed Web of Science ®Google Scholar
• Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996;74: 63–8.
   Google Scholar
• Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 1983;67:889–94.
   PubMedGoogle Scholar
• Ueda K, Cardaralli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human "MDR-1" gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004–8.
   PubMed Web of Science ®Google Scholar
• Bourgeois S, Gruol DJ, Newby BRF, Rajah FM. Expression of an mdr gene is associated with a new form of resistance to dexametha-sone-induced apoptosis. Mol Endocrinol 1993;7:840–51.
   PubMed Web of Science ®Google Scholar
• Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER. Penetration of dexamethasone into brain glucocorti-cold targets is enhanced in mdrl A P-glycoprotein knockout mice. Endocrinology 1998;139:1789–93.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Minami Y, Mine S, Hirano H, Hu CD, Fujimoto H, et al. H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. J Immunol 1999;163:6209–16.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Wake A, Horgan KJ, Murakami S, Aso M, Saito K, et al. Distinct phenotype of leukemic T cells with various tissue tropisms. J Immunol 1997;158:3822–9.
   PubMed Web of Science ®Google Scholar
• Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986;83:7785–9.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kimata K, Wake A, Mine S, Morimoto I, Yamakawa N, et al. Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endot-helial cells. J Exp Med 1996;184:1987–97.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Ftheumatology revised criteria for the classification of systemic lupus erythemato-sus. Arthritis Rheum 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.
   Google Scholar
• Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521–30.
   PubMed Web of Science ®Google Scholar
• Morand EF. Corticosteroids in the treatment of rheumatologic diseases. Curr Opin Ftheumatol 2000;12:171–7.
   PubMed Web of Science ®Google Scholar
• Hahn BH. Systemic lupus erythematosus. In: Braunwald E, Fauci AS, Kasper DL, Hauser SI, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. 15th ed. Columbus: McGraw-Hill; 2001. p. 1922–8.
   Google Scholar
• Siiteri PK, Mural JT, Hammond GL, Nisker JA, Raymoure WJ, Kuhn RW. The serum transport of steroid hormones. Recent Prog Horm Res 1982;38:457–510.
   PubMedGoogle Scholar
• Mader R, Schonfeld S. Malabsorption in systemic lupus erythema-tosus. Harefuah 1990;118:572–3.
   PubMedGoogle Scholar
• Altomonte L, Zoli A, Alessi F, Ghirlanda G, Greco AV, Magaro M. Gastroenterologic aspects of connective tissue diseases. Minerva Med 1985;76:1323–9.
   PubMedGoogle Scholar
• Kawai S. A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy (in Japanese). Nippon Naibunpi Gakkai Zasshi 1985;61:145–61.
   PubMedGoogle Scholar
• Kelly E, Won A, Refaeli Y, Van Parijs L. IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol 2002;168: 597–603.
   Google Scholar
• Luxembourg AT, Cooper NR. T cell-dependent, B cell-activating properties of antibody-coated small latex beads. A new model for B cell activation. J Immunol 1994;153:604–14.
   PubMed Web of Science ®Google Scholar
• Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: lack of asso-ciations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Ftheumatol 2002;29:482–6.
   Google Scholar
• Dau PC, Callahan J, Parker R, Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in sys-temic lupus erythematosus. J Ftheumatol 1991;18:270–6.
   Google Scholar
• Tanaka Y, Saito K, Shirakawa F, Ota T, Suzuki H, Eto S, et al. Production of B cell stimulating factors by B cells in patients with systemic lupus erythematosus. J Immunol 1988;141:3043–9.
   PubMed Web of Science ®Google Scholar
• Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, et al. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells: in press.
   Google Scholar
• Bommhardt U, Cerottini JC, MacDonald HR. Heterogeneity in P-glycoprotein (multidrug resistance) activity among murine peripheral T cells: correlation with surface phenotype and effector function. Eur J Immunol 1994;24:2974–81.
   Google Scholar
• Su CC, Shau WY, Wang CR, Chuang CY, Chen CY. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity. Lupus 1997;6: 449–54.
   Google Scholar
• Farrell FtJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003;178:339–46.
   PubMed Web of Science ®Google Scholar
• Montano E, Schmitz M, Blaser K, Simon HU. P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma. J Invest Allergol Chin Immunol 1996;6:14–21.
   PubMed Web of Science ®Google Scholar